{
    "organizations": [],
    "uuid": "b3df562b88f994e2d5a5095c62aa50af3028d57d",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/03/globe-newswire-intelgenx-to-report-first-quarter-2018-financial-results-on-may-10-2018-a-conference-call-to-follow.html",
    "ord_in_thread": 0,
    "title": "IntelGenx to Report First Quarter 2018 Financial Results on May 10, 2018 – Conference Call to Follow",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SAINT LAURENT, Quebec, IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) today announced that it will release its first quarter 2018 financial results after market close on May 10, 2018.\nAn accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:\nDate: Thursday, May 10, 2018\nTime: 4:30 p.m. ET\nConference dial-in: (833) 231-8269\nInternational dial-in: (647) 689-4114\nConference ID: 2398086\nWebcast Registration: Click here\nFollowing the live call, a replay will be available on the Company's website, www.intelgenx.com , under \"Investor Relations\".\nAbout IntelGenx:\nEstablished in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.\nIntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com .\nEach of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.\nSource: IntelGenx Technologies Corp.\nFor more information, please contact: Stephen Kilmer Investor Relations (514) 331-7440 ext 232 stephen@intelgenx.com Or Andre Godin, CPA, CA Executive Vice-President and CFO IntelGenx Corp. (514) 331-7440 ext 203 andre@intelgenx.com\nSource:IntelGenx Corp.",
    "published": "2018-05-04T00:00:00.000+03:00",
    "crawled": "2018-05-04T02:49:27.037+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "saint",
        "laurent",
        "quebec",
        "intelgenx",
        "technology",
        "tsx",
        "venture",
        "igx",
        "otcqx",
        "igxt",
        "today",
        "announced",
        "release",
        "first",
        "quarter",
        "financial",
        "result",
        "market",
        "close",
        "may",
        "accompanying",
        "conference",
        "call",
        "hosted",
        "horst",
        "zerbe",
        "president",
        "chief",
        "executive",
        "officer",
        "andre",
        "godin",
        "executive",
        "chief",
        "financial",
        "officer",
        "discus",
        "result",
        "provide",
        "business",
        "update",
        "detail",
        "conference",
        "call",
        "webcast",
        "date",
        "thursday",
        "may",
        "time",
        "et",
        "conference",
        "international",
        "conference",
        "id",
        "webcast",
        "registration",
        "click",
        "following",
        "live",
        "call",
        "replay",
        "available",
        "company",
        "website",
        "investor",
        "relation",
        "intelgenx",
        "established",
        "intelgenx",
        "leading",
        "oral",
        "drug",
        "delivery",
        "company",
        "primarily",
        "focused",
        "development",
        "manufacturing",
        "innovative",
        "pharmaceutical",
        "oral",
        "film",
        "based",
        "proprietary",
        "technology",
        "platform",
        "intelgenx",
        "highly",
        "skilled",
        "team",
        "provides",
        "comprehensive",
        "pharmaceutical",
        "service",
        "pharmaceutical",
        "partner",
        "including",
        "r",
        "analytical",
        "method",
        "development",
        "clinical",
        "monitoring",
        "ip",
        "regulatory",
        "service",
        "intelgenx",
        "manufacturing",
        "facility",
        "established",
        "technology",
        "platform",
        "support",
        "pilot",
        "production",
        "offering",
        "full",
        "service",
        "capability",
        "client",
        "information",
        "company",
        "found",
        "tsx",
        "venture",
        "exchange",
        "otcqx",
        "neither",
        "approved",
        "disapproved",
        "content",
        "press",
        "release",
        "neither",
        "tsx",
        "venture",
        "exchange",
        "regulation",
        "service",
        "provider",
        "term",
        "defined",
        "policy",
        "tsx",
        "venture",
        "exchange",
        "accepts",
        "responsibility",
        "adequacy",
        "accuracy",
        "release",
        "source",
        "intelgenx",
        "technology",
        "information",
        "please",
        "contact",
        "stephen",
        "kilmer",
        "investor",
        "relation",
        "ext",
        "stephen",
        "andre",
        "godin",
        "cpa",
        "ca",
        "executive",
        "cfo",
        "intelgenx",
        "ext",
        "andre",
        "source",
        "intelgenx",
        "corp"
    ]
}